Purpose:
To determine if eptinezumab is a safe and effective treatment for those who suffer from episodic Cluster headache
Key Criteria:
▪ adult (18-75) with episodic cluster headache diagnosis
▪ reliable history of previous acute and preventative medication use for eCH for at least 12 months
▪ prior history of cluster period(s) lasting ≥ 6 weeks
▪ no previous failure of anti-CGRP therapies
▪ anti-CGRP therapies disallowed for 5 months for mAbs and 1 month for gepants prior to screening
▪ no oral steroids or GON blocks 30 days prior to screening until end of week 4
▪ willing to have 2 vyepti infusions, one of which is placebo
Join the Study
If you fit the key criteria and are interested in joining the study please email us at research@diamondheadache.com